Back to Results
First PageMeta Content
Medicine / Rare diseases / Motor neurone disease / Amyotrophic lateral sclerosis / Gene therapy / James Heywood / Biology / ALS Therapy Development Institute / Health


Media Contact: Robert Goldstein, ALS TDI, 617
Add to Reading List

Document Date: 2009-02-05 10:56:40

Open Document

File Size: 17,33 KB

Share Result on Facebook

City

CAMBRIDGE / /

Company

RGK Foundation / MDA / Augie’s Quest / /

Country

United States / /

Currency

USD / /

/

Event

Business Partnership / FDA Phase / /

Facility

ALS Therapy Development Institute The ALS Therapy Development Institute / FOR IMMEDIATE RELEASE ALS Therapy Development Institute / ALS Therapy Development Institute / /

IndustryTerm

gene therapy technology / biotechnology / gene therapy technologies / /

MedicalCondition

Lou Gehrig’s disease / disease / neurodegenerative disease / ALS / progressive paralysis / novel disease / amyotrophic lateral sclerosis / relentless disease / multiple sclerosis / /

MedicalTreatment

gene therapy / /

Organization

ALS / ALS Therapy Development Institute / FDA / RGK Foundation of Austin / FOR IMMEDIATE RELEASE ALS Therapy Development Institute / /

Person

Steve Perrin / Lou Gehrig / Robert Goldstein / /

/

Position

Chief Scientific Officer / Ronya Kozmetsky co-founder / /

Product

only one FDA-approved drug / /

ProvinceOrState

Texas / Massachusetts / /

Technology

gene therapy technologies / Knowledge Management System / drug discovery / gene therapy technology / biotechnology / /

URL

www.als.net / /

SocialTag